All In Biotech

Drug Trial Radar · NCT05425732

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,663 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,663

Actual

Start

Jul 13, 2022

Primary completion

May 18, 2023

Study completion May 18, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine (\[Prevnar 20™ / APEXXNAR™\]) in pneumococcal vaccine-naïve adults. It is hypothesized that V116 is noninferior to PCV20 for the common serotypes and superior to PCV20 for the unique serotypes as assessed by serotype specific opsonophagocytic activity (OPA) 30 days postvaccination. It is also hypothesized that V116 in participants 18 to 49 years of age immunobridges to V116 in participants 50 to 64 years of age as assessed by serotype specific OPA geometric mean titers (GMTs) 30 days postvaccination for all 21 serotypes in V116. Participants ≥50 years of age will be enrolled in Cohort 1, and participants 18 to 49 years of age will be enrolled in Cohort 2.

Conditions

  • Pneumococcal Infection

Interventions

  • V116Biological

    0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.

  • PCV20Biological

    0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days post-vaccination
  2. Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days post-vaccination
  3. Percentage of Participants With Vaccine-related Serious AE (SAE)Time frame: Up to 194 days post-vaccination
  4. Serotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20Time frame: Day 30 post-vaccination
  5. Percentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses in Cohort 1 Only for the 11 Unique Pneumococcal Serotypes Contained in V116Time frame: Baseline and Day 30 post-vaccination
  6. Serotype Specific OPA GMTs in Participants 18-49 Years and Participants 50-64 Years for the Pneumococcal Serotypes Contained in V116Time frame: Day 30 post-vaccination

Locations

112 sites in 11 countries. Site status is shown where the registry gives one.

  • Central Research Associates ( Site 0067)

    Birmingham, Alabama

  • Lenzmeier Family Medicine/CCT Research ( Site 0006)

    Glendale, Arizona

  • Desert Clinical Research/ CCT Research ( Site 0040)

    Mesa, Arizona

  • Foothills Research Center/ CCT Research ( Site 0021)

    Phoenix, Arizona

  • Fiel Family and Sports Medicine, PC/CCT Research ( Site 0003)

    Tempe, Arizona

  • Baptist Health Center For Clinical Research ( Site 0019)

    Little Rock, Arkansas

  • Southland Clinical Research Center-Research ( Site 0054)

    Fountain Valley, California

  • Sunwise Clinical Research ( Site 0024)

    Lafayette, California

  • Chemidox Clinical Trials ( Site 0048)

    Lancaster, California

  • Paradigm Clinical Research Centers, Inc ( Site 0018)

    Redding, California

  • Peninsula Research Associates ( Site 0079)

    Rolling Hills Estates, California

  • Acclaim Clinical Research ( Site 0083)

    San Diego, California

  • Millennium Clinical Trials ( Site 0013)

    Simi Valley, California

  • Lynn Institute of Denver ( Site 0012)

    Aurora, Colorado

  • Paradigm Clinical Research Centers, Inc ( Site 0027)

    Wheat Ridge, Colorado

  • JEM Research Institute ( Site 0072)

    Atlantis, Florida

  • Alliance for Multispecialty Research, LLC ( Site 0015)

    Coral Gables, Florida

  • Hillcrest Medical Research ( Site 0049)

    DeLand, Florida

  • East Coast Institute for Research, LLC ( Site 0070)

    Jacksonville, Florida

  • East Coast Institute for Research ( Site 0071)

    Lake City, Florida

  • L&C Professional Medical Research Institute ( Site 0025)

    Miami, Florida

  • Advanced Medical Research Institute ( Site 0014)

    Miami, Florida

  • Headlands Research Orlando ( Site 0031)

    Orlando, Florida

  • Genesis Clinical Research, LLC ( Site 0016)

    Tampa, Florida

  • Clinical Research Trials of Florida ( Site 0007)

    Tampa, Florida

  • Palm Beach Research Center ( Site 0060)

    West Palm Beach, Florida

  • Clinical Research Prime ( Site 0010)

    Idaho Falls, Idaho

  • Solaris Clinical Research ( Site 0008)

    Meridian, Idaho

  • Versailles Family Medicine / CCT Research ( Site 0063)

    Versailles, Kentucky

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0038)

    Troy, Michigan

  • Alliance for Multispecialty Research, LLC ( Site 0026)

    Kansas City, Missouri

  • Skyline Medical Center/CCT Research ( Site 0028)

    Elkhorn, Nebraska

  • Methodist Physicians Clinic/CCT Research ( Site 0058)

    Fremont, Nebraska

  • Meridian Clinical Research, LLC ( Site 0045)

    Norfolk, Nebraska

  • Healor Primary Care / CCT Research ( Site 0056)

    Las Vegas, Nevada

  • Excel Clinical Research, LLC ( Site 0077)

    Las Vegas, Nevada

  • Santa Rosa Medical Centers of Nevada / CCT Research ( Site 0029)

    Las Vegas, Nevada

  • Smith Allergy & Asthma Specialists-Corning Center for Clinical Research ( Site 0032)

    Horseheads, New York

  • Aventiv Research Inc ( Site 0044)

    Columbus, Ohio

  • Advanced Medical Research ( Site 0002)

    Maumee, Ohio

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.